Publikationen

41. Karakas M, Jaensch A, Breitling LP, Brenner H, Koenig W, Rothenbacher D. Prognostic value of midregional pro A-type natriuretic peptide and N-terminal pro B-type natriuretic peptide in patients with stable coronary heart disease followed over 8 years. Clinical Chemistry (im Druck).

40. Rothenbacher D, Jaensch A, Mons U, hahmann H, Becker T, Koenig W, Brenner H. Prognostic value of one-year course of symptoms of anxiety and depression in patients with coronary heart disease. role of physical activity and unmet medical need. European Journal of Preventive Cardiology (im Druck).

39. Mons U, Hahmann H, Brenner H. A reverse J-shaped association of leisure time physical activity with prognosis in patients with stable coronary heart disease: evidence from a large cohort with repeated measurements. Heart 2014; 100:1043-1049.

38. Rothenbacher D, Hoffmann MM, Breitling LP, Rajman I, Koenig W, Brenner H. Cytochrome p450 2C19*2 polymorphism in patients with stable coronary heart disease and risk for secondary cardiovascular disease events: results of a long-term follow-up study in routine clinical care. BMC Cardiovascular Disorders. 2013; 13:61.

37.Siegerink B, Maas R, Vossen CY, Schwedhelm E, Koenig W, Rothenbacher D, Brenner H, Breitling LP. Assymetric and symmetric dimethylarginine and risk of secondary cardiovascular disease events and mortality in patients with stable coronary heart disease: the KAROLA follow-up study. Clinical Research in Cardiology 2013; 102:193-202

36. Breitling LP, Salzmann K, Rothenbacher D, Burwinkel B, Brenner H. Smoking, F2RL3 methylation and prognosis in stable coronary heart disease. European Heart Journal 2012; 33;2841-2848.

35. Rothenbacher D, Kleiner A, Koenig W, Primatesta P, Breitling LP, Brenner H. Relationship between inflammatory cytokines and uric acid levels with adverse cardiovascular outcomes in patients with stable coronary heart disease. PLoS One 2012;7:e45907.

34. Koenig W, Breitling LP, Hahmann H, Wüsten B, Brenner H, Rothenbacher D. Cardiac troponin T measured by a high-sensitivity assay predicts recurrent cardiovascular events in stable coronary heart disease patients with 8-year follow up. Clinical Chemistry 2012;58:1215-1224.

33. Von Eynatten M, Breitling LP, Roos M, Baumann M, Rothenbacher D, Brenner H. Circulating adipocyte fatty acid-binding protein levels and cardiovascular morbidity and mortality in patients with coronary heart disease: a 10-year prospective study. Arteriosclerosis, Thrombosis, and Vascular Biology 2012;32:2327-2335.

32. Grandi NC, Brenner H, Hahmann H, Wüsten B, März W, Rothenbacher D, Breitling LP. Calcium, phosphate, and the risk of cardiovascular events and all-cause mortality in a population with stable coronary heart disease. Heart 2012;98:926-933.

31. Grandi NC, Breitling LP, Hahmann H, Wüsten B, Märtz W, Rothenbacher D, Brenner H. Serum parathyroid hormone and risk of adverse outcomes in patients with stable coronary heart disease. Heart 2011;97:1215-1221.

30. Breitling LP, Rothenbacher D, Grandi NC, März W, Brenner H. Prognostic usefulness of free fatty acids in patients with stable coronary heart disease. American Journal of Cardiology 2011;108:508-513.

29. Breitling LP, Koenig W, Fischer M, Mallat Z, Hengstenberg C, Rothenbacher D, Brenner H. Type II secretory phospholipase A2 and prognosis in patients with stable coronary heart disease: Mendelian randomization study. PloS One 2011;6:e22318.

28. Breitling LP, Rothenbacher D, Vossen CY, Hahmann H, Wüsten B, Brenner H. Validated smoking cessation and prognosis in patients with stable coronary heart disease. Journal of the American College of Cardiology 2011;58:196-197.

27. Grandi NC, Breitling LP, Vossen CY, Hahmann H, Wüsten B, März W, Rothenbacher D, Brenner H. Serum vitamin D and risk of secondary cardiovascular disease events in patients with stable coronary heart disease. American Heart Journal 2010;40:616-622.

26. Roos M, von Eynatten M, Heemann U, Rothenbacher D, Brenner H, Breitling LP. Serum fetuin-A, cardiovascular risk factors, and six-year follow-up outcome in patients with coronary heart disease. American Journal of Cardiology 2010;105:1666-1672.

25. Duwensee K, Breitling LP, Tancevski I, Rothenbacher D, Demetz E, Patsch JR, Ritsch A, Eller P, Brenner H. Cholesteryl ester transfer protein in patients with coronary heart disease. European Journal of Clinical Investigation 2010;40:616-622.

24. Breitling LP, Grandi NC, Hahmann H, Wüsten B, Rothenbacher D, Brenner H. Gamma-glutamyltransferase and prognosis in patients with stable coronary heart disease followed over 8 years. Atherosclerosis. 2010;210:649-55.

23. The Lp-PLA2 Studies Collaboration. Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 2010;375:1536-1544.

22. Koenig W, Vossen CY, Mallat Z, Brenner H, Benessiano J, Rothenbacher D. Association between type II secretory phospholipase A2 plasma concentrations and activity and cardiovascular events in patients with coronary heart disease. European Heart Journal 2009;30:2742-2748.

21. Von Eynatten M, Hamann A, Twardella D, Nawroth P, Brenner H, Rothenbacher D. Atherogenic dyslipidemia but not total and high molecular weight adiponectin are associated with the prognostic outcome in patients with coronary heart disease. European Heart Journal 2008;29:1307-1315.

20. Vossen CY, Hoffmann MM, Hahmann H, Wüsten B, Rothenbacher D, Brenner H. Effect of APOE genotype on lipid levels in patients with coronary heart disease during a 3-week in-patient rehabilitation program. Clinical Pharmacology and Therapeutics 2008;84:222-227.

19. Rothenbacher D, Hahmann H, Wüsten B, Koenig W, Brenner H. Symptoms of anxiety and depression in patients with stable coronary heart disease: prognostic value and consideration of pathogenetic links. European Journal of Cardiovascular Prevention and Rehabilitation 2007;14:547-554.

18. Rothenbacher D, Koenig W, Brenner H. Comparison of N-terminal pro-B-natriuretic peptide, C-reactive protein, and creatinine clearance for prognosis in patients with known coronary heart disease. Archives of Internal Medicine 2006; 166: 2455-2460.

17. Guech-Ongey M, Brenner H, Twardella D, Rothenbacher D. Chlamydia pneumoniae, heat shock proteins 60 and risk  of secondary cardiovascular events  in patients with coronary heart disease under special consideration of diabetes : a prospective study. BMC Cardiovascular Disorders 2006; 6: 17.

16. Guech-Ongey M, Brenner H, Twardella D, Hahmann H, Rothenbacher D. Role of cytomegalovirus sero-status in the development of secondary cardiovascular events in patients with cardiovascular disease under special consideration of diabetes. International Journal of Cardiology 2006; 111: 98-103.

15. Küpper-Nybelen J, Rothenbacher D, Brenner H. Relationship between lifetime alcohol consumption and Helicobacter pylori infection. Annals of Epidemiology 2005; 15: 607-613.

14. Koenig W, Twardella D, Brenner H, Rothenbacher D. Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function and hemodynamic stress.
Arteriosclerosis, Thrombosis and Vascular Biology 2006; 26: 1586-1593.

13. Von Eynatten M, Hamann A, Twardella D, Nawroth PP, Brenner H, Rothenbacher D. Relationship of adiponectin with markers of systemic inflammation, atherogenic dyslipidemia and heart failure in patients with coronary heart disease. Clinical Chemistry 2006; 52: 797-799.

12. Loew M, Hoffmann MM, Koenig W, Brenner H, Rothenbacher D. Genotype and plasma concentration of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events. Arteriosclerosis, Thrombosis and Vascular Biology 2005; 25: 1470-1474.

11. Koenig W, Twardella D, Brenner H, Rothenbacher D. Plasma Concentrations of Cystatin C in Patients with Coronary Heart Disease and Risk for Secondary Cardiovascular Events: More Than Simply a Marker of Glomerular Filtration Rate. Clinical Chemistry 2005; 51:321-327.

10. Twardella D, Merx H, Hahmann H, Wüsten B, Rothenbacher D, Brenner H. Long-term adherence to dietary recommendations after in-patient rehabilitation: prospective follow-up study in patients with coronary heart disease. Heart 2006;92:635-640.

9. Loew M, Hoffmann MM, Hahmann H, März W, Rothenbacher D, Brenner H. Smoking, Apolipoprotein E genotype, and early onset of coronary heart disease. European Journal of Cardiovascular Prevention and Rehabilitation 2005; 12: 268-270.

8. Twardella D, Rothenbacher D, Hahmann H, Wüsten B, Brenner H. The underestimated impact of smoking and smoking cessation on the risk of secondary cardiovascular disease events in patients with stable coronary heart disease: prospective cohort study. The Journal of the American College of Cardiology 2006; 47: 887-889.

7. Twardella D, Küpper-Nybelen J, Rothenbacher D, Hahmann H, Wüsten B, Brenner H.
Short-term benefit of smoking cessation in patients with coronary heart disease: estimates based on self-reported smoking data and serum cotinine measurements. European Heart Journal 2004; 25: 2101-2108.

6. Hahmann HW, Wüsten B, Nuß B, Muche R, Gaus W, Rothenbacher D, Brenner H. INKA, eine randomisierte Studie zur kardiologischen Reha-Nachsorge. Herzmedizin 2004; 21: 109

5. Hahmann HW, Wüsten B, Nuß B, Muche R, Gaus W, Rothenbacher D, Brenner H. Intensivierte Kardiologische Reha-Nachsorge bei Patienten mit Koronarer Herzkrankheit - die Ergebnisse der INKA-Studie. Perfusion 2004;17: 71-72.

4. Hahmann HW, Wüsten B, Nuß B, Muche R, Gaus W, Rothenbacher D, Brenner H. Intensivierte Reha-Nachsorge nach stationärer Anschlussheilbehandlung bei Patienten mit Koronarer Herzkrankheit Die Ergebnisse der INKA-Studie. In: Verband der Deutschen Rentenversicherungsträger (Hrsg.). Selbstkompetenz, Weg und Ziel der Rehabilitation.
DRV-Schriften Bd. 52, Frankfurt, 2004:181-183.

3. Küpper-Nybelen J, Rothenbacher D, Jacobi E, Brenner H. Die prognostische Bedeutung von Variablen aus dem Qualitätssicherungsprogramm und  dem Reha-Entlassungsbericht der LVA-Württemberg für die Erwerbs- oder Berufsunfähigkeit: Ergebnisse einer retrospektiven Kohortenstudie. Die Rehabilitation 2003; 42: 335-342.

2. Rothenbacher D, Reitinger A, Hahmann H, Nischan P, Brenner H. Auswirkungen einer stationären Reha-Maßnahme auf kardiovaskuläre Risikofaktoren bei Patienten mit Koronarer Herzkrankheit und prognostische Bedeutung in Bezug auf gesundheitsbedingte Frühberentung und Sterblichkeit: Ergebnisse einer Kohortenstudie. DRV-Schriftenreihe 2001; 26: 324-325.

1. Küpper-Nybelen J, Rothenbacher D, Hahmann H, Wüsten B, Brenner H. Veränderungen von Risikofaktoren während und ein Jahr nach stationärer Rehabilitation bei Patienten mit koronarer Herzkrankheit. Deutsche Medizinische Wochenschrift 2003; 128: 1525-1530.


 

nach oben